Pack of 14, 130 mg Tablets.
iOSAT™ is the first radiation protective tablet available to the general public. Experts agree that its prompt use would be the most effective way to protect millions of people who would be at risk in a nuclear accident or under a radiation threat from a nuclear weapon. They are FDA approved tablets that contain potassium iodide (KI) which provides protection from radioactive iodine (RAI), the contaminant that causes thyroid cancer.
iOSAT™ received its approval from the US Food and Drug Administration in 1982 and is the only full-strength table for radiation blocking. Only iOSAT™ has passed all FDA tests for purity, quality, safety and efficacy.
A single dose protects the thyroid gland for 24 hours. The shelf life of IOSAT 130 mg tablets is 7 years.
CAUTION: There are possible side effects so individuals with known iodide sensitivity or who have conditions associated with increased risk of iodine hypersensitive should avoid taking KI. Consult your physicians to determine sensitivity or conditions prior to an emergency. FDA recommends that neonates (newborn to one month), pregnant and lactating women, and those with iodine sensitivity, should be given priority to other protective measures during an emergency. Follow all dosage guidelines based on your risk group or consult your doctor.